Phuturdex › Listed companies › Kura Oncology, Inc.
Companies listed in the US · updated 13 November 2026
Kura Oncology, Inc.: drugs in development, dates and SEC filings
Data from official sources, not financial advice.
As of 13 November 2026 Kura Oncology, Inc. sponsors 7 active clinical trials (recruiting or ongoing, phases I–III) on 16 identified drugs. One is experimental (not yet approved in the United States).
Official links
Pipeline by phase
Drugs in the active trials sponsored by Kura Oncology, Inc., with the most advanced phase of those trials. Sorted by phase and number of trials.
| Drug | Most advanced phase | Main diseases |
|---|---|---|
| Darlifarnib | I | Renal cell carcinoma, Kidney neoplasm |
Drugs already approved in the US in the company’s trials: 15. Full list with trials, reference trial, dates, patents and events in Phuturdex. Sign up free to see everything →
Upcoming dates
Expected primary completion of the company’s phase II and III trials (12 months, date stated by the sponsor on ClinicalTrials.gov) and regulatory dates of the products the company holds (36 months).
No date in the coming months in the linked official sources.
US exclusivities and patents expiring
Products whose FDA application is held by the company (Orange Book or Purple Book), expiring in the next 36 months.
No US patent or exclusivity expiring in the next 36 months for the products the company holds.
Recent events (last 12 months)
The company’s trials terminated, suspended or withdrawn and new phase III trials (ClinicalTrials.gov); approvals, opinions and designations of the products the company holds (FDA, EMA).
Events in the last 12 months: 1. The latest is shown below. Sign up free to see everything →
| Date | Drug | What | Source |
|---|---|---|---|
| 13 Nov 2025 | Ziftomenib | First FDA approval of the substance: Komzifti (NDA220305). | Drugs@FDA |
Financial figures from the latest SEC report
Figures as reported by the company in its SEC filing (XBRL data), in the currency of the filing, with no Phuturdex calculation. Quarter: 10-Q report for the period ended 30 September 2026, filed 10 November 2026.
| Item | Value | Period | Filing |
|---|---|---|---|
| Cash and cash equivalentsus-gaap:CashAndCashEquivalentsAtCarryingValue | USD 57.9 million | at 30 September 2026 | 10-Q · 10 Nov 2026 |
| Research and development expenseus-gaap:ResearchAndDevelopmentExpense | USD 66.9 million | 1 July 2026 to 30 September 2026 | 10-Q · 10 Nov 2026 |
| Revenue from contracts with customersus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | USD 22.8 million | 1 July 2026 to 30 September 2026 | 10-Q · 10 Nov 2026 |
Recent SEC filings
| Filing | Filed | Reference date |
|---|---|---|
| 10-Q | 10 Nov 2026 | 30 Sep 2026 |
| 8-K | 10 Nov 2026 | 10 Nov 2026 |
| 8-K | 9 Sep 2026 | 9 Sep 2026 |
| 8-K | 8 Sep 2026 | 8 Sep 2026 |
| 10-Q | 12 Aug 2026 | 30 Jun 2026 |
| 8-K | 12 Aug 2026 | 12 Aug 2026 |
All the data on Kura Oncology, Inc.
In Phuturdex you get every trial of the company with countries and dates, the catalyst calendar, email alerts when something changes and PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Sources: SEC EDGAR (exchange, ticker, filings and XBRL financial data, US Government works); ClinicalTrials.gov (U.S. National Library of Medicine), FDA (Drugs@FDA, Orange and Purple Book, orphan drugs) and EMA, data processed by Phuturdex and updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III. The sponsor is the one stated by each trial; company names are linked to the SEC only when they are the same apart from the legal form. Patents, exclusivities, approvals and opinions are attributed to the company only when it holds them in the official register. No stock prices or charts. Only the official sources are authoritative.
Data from official sources, not financial advice.